Grant of PDMR Options

RNS Number : 8614E

Instem plc

15 March 2022

 

 

Instem plc

("Instem" or "the Company")

Grant of PDMR Options

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have each been granted awards of nil-cost options over 4,833 and 2,165 Ordinary Shares respectively under the Instem plc 2018 Long Term Incentive Plan ("LTIP").  These options will ordinarily vest and become exercisable on 1 January 2025 pursuant to the rules of the LTIP.

After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 133,649 and 261,696 Ordinary Shares, respectively. 

For further information, please contact:

Instem plc	via Walbrook
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel Rachel Hayes Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Phil Reason
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Grant of nil cost options under the Company's LTIP
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Grant of nil cost options under the Company's LTIP
c)	Price(s) and volume(s)
			Price	Volume(s)
			Nil	4,833
d)	Aggregated information
	- Aggregated volume	N/A - Single transaction
	- Price
e)	Date of the transaction	7th March 2022
f)	Place of the transaction	Off-market transaction

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nigel Goldsmith
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Grant of nil cost options under the Company's LTIP
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			Nil	2,165
d)	Aggregated information	N/A - Single Transaction
	- Aggregated volume
	- Price
e)	Date of the transaction	11th March 2022
f)	Place of the transaction	Off-market transaction

About Instem  

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

DSHUVSORUAUOAAR